Pharmacological characterization of orally active cholinesterase inhibitory activity of Prunus persica L. Batsch in rats

Journal of Molecular Neuroscience

Volumn 29, Issue 2, 2006, Pages 101-107

  Suh, Seok Jong ^a   Koo, Byung Soo ^b   Jin, Un Ho ^a   Hwang, Moon Je ^a,b   Lee, In Seon ^c   Kim, Cheorl Ho ^a  

^a Sungkyunkwan University   (South Korea)

^b Dongguk University   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Alzheimer's disease; Cholinesterase; Cholinesterase inhibitor; Donepezil; iso OMPA; PPE; Tacrine

Indexed keywords

CHOLINESTERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; ISO OMPA; METHANOL EXTRACTION RESIDUE; PLANT EXTRACT; PRUNUS PERSICA EXTRACT; TACRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME INHIBITION; FRACTIONATION; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PLASMA; PRUNUS; RAT;

ACETYLCHOLINESTERASE; ADMINISTRATION, ORAL; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; INDANS; MALE; PIPERIDINES; PLANT EXTRACTS; PRUNUS; RATS; RATS, WISTAR; TACRINE; TISSUE EXTRACTS;

PRUNUS PERSICA;

EID: 33748441948     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/JMN:29:2:101     Document Type: Article

References (24)

1. Akgur S. A., Ozturk P., Sozmen E. Y., Delen Y., Tanyalcin T., and Ege B. (1999) Paraoxonase and acetylcholinesterase activities in humans exposed to organophosphorous compounds, J. Toxicol. Environ. Health 58, 469-474.
2. Cohen R. and Barenholz Y. (1984) Characterization of the association of Electrophorus electricus acetylcholinesterase with sphingomyelin liposomes. Relevance to collagen-sphingomyelin interactions, Biochim. Biophys. Acta 778, 94-104.
3. Davis P. and Maloney A. J. (1976) Selective loss of central cholinergic neurons in Alzheimer disease. Lancet 2(8000), 1403.
4. Drachman D.A. (1977) Memory and cognitive function in man: does the cholinergic system have a specific role. Neurology 27, 783-790.
5. Edwards J. A. and Brimijoin S. (1982) Divergent regulation of acetylcholinesterase and butyrylcholinesterase in tissues of the rat. J. Neurochem. 38, 1393-1403.
6. Ellman G. L., Courtney D., Andres V. Jr., and Featherstone R. M. (1961) Anew and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95.
7. Fang X. D. (1986) Active protein constituents from the kernel of Prunus persica. Zhong Yao Tong Bao 11(11), 37-39.
8. Forette F., Anand R., and Gharabawi G. (1999) Aphase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). Eur. J. Neurol. 6, 423-429.
9. Fuhrman B., Partoush A., and Aviram M. (2004) Acetylcholine esterase protects LDL against oxidation. Biochem. Biophys. Res. Commun. 322(3), 974-978.
10. Gilani A. H., Aziz N., Ali S. M., and Saeed M. (2000) Pharmacological basis for the use of peach leaves in constipation. J. Ethnopharmacol. 73, 87-93.
11. Hass M. A., Nowak D. M., Leonova E., Levin R. M., and Longhurst P. A. (1999) Identification of components of Prunus africana extract that inhibit lipid peroxidation. Phytomedicine 6(5), 379-388.
12. Heo J., 1991. Dong-eui-bo-gam. Nam-san-dang Publishing Co., Seoul, Korea. p. 712.
13. Kim H. J., Lee W. H., Yoon C. H., Jeong J. C., Nam K. S., Kim H. M., et al. (2001). Bombycis corpus extract prevents amyloid-beta-induced cytotoxicity and protects superoxide dismutase activity in cultured rat astrocytes. Pharmacol. Res. 43, 11-16.
14. Kosasa T., Kuriya Y., Matsu K., and Yamanishi Y. (2000) Inhibitory effect of orally administered tacrine, a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur. J. Pharmacol. 389, 173-179.
15. Menache R., Kenda L., Shaked P., Schwartzman S., and Lewinski U. (1982) The prognostic value of serum acetylcholinesterase in myocardial infarction. Theoretical and clinical considerations. Res. Exp. Med. (Berl.) 181, 181-187.
16. Nordberg A. and Svensson A. L. (1998) Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Safety 19, 465-480.
17. Perry E. K., Tomlinson B. E., Blessed G., Bergma, K., Gibson P. H., and Perry R. H. (1978) Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 2, 1456-1459.
18. Rogers S. L., Farlow M. R., Doody R. S., Mohs R., and Friedhoff L. T. (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50, 136-145.
19. Shen D., Shen L., and Wang A. L. (1994) Effect of xiaoyu pian on new platelet aggregation defect. Zhongguo Zhong Xi Yi Jie He Za Zhi 14, 589-591.
20. Sherman K. A. (1991) Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches, in Cholinergic Basis for Alzheimer Therapy, Becker, R., and Giacobini, E., eds., Birkhauser, Boston, MA, pp. 321-328.
21. Summers W. K., Majovski L. V., Marsh G. M., Tachiki K., and Kling A. (1986) Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer's type. N. Engl. J. Med. 315, 1241-1245.
22. Weiner L., Kreimer D., Roth E., and Silman I. (1994) Oxidative stress transforms acetylcholinesterase to a molten-globule-like state, Biochem. Biophys. Res. Commun. 198, 915-922.
23. White P., Hiley C. R., Goodhardt M. J., et al. (1977) Neocortical cholinergic neurons in elderly people. Lancet 1(8013), 668-671.
24. Wilcock G. K., Lilienfeld S., and Gaens E. (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine Inernational-1 Study Group. Br. Med. J. 321, 1445-1449.